LAWRENCE, Mass., June 21, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jay W. Shreiner has been appointed to its Board of Directors effective immediately.
Most recently, Mr. Shreiner served as Interim Chief Financial Officer for Behavioral Centers of America from April 2012 until its acquisition by Acadia Healthcare in December 2012. From 2006 to 2011, Mr. Shreiner was the Executive Vice President and Chief Financial Officer at RehabCare Group, Inc., a NYSE publicly traded healthcare services company that was acquired by Kindred Healthcare in 2011. His career experiences include Ernst & Young, the B.F. Goodrich Company and 16 years at the Kellogg Company where he served on the Company's Global Strategic Leadership Team. Mr. Shreiner was also Chief Financial Officer for several private companies within Austin Ventures' portfolio of companies.
"We are thrilled to have someone with Jay's broad experience join our board. Jay's operational and financial expertise within healthcare services will be highly relevant as we work to accelerate adoption of our life changing therapy," stated Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc.
"I'm looking forward to working with Jeff and NxStage's management team to help achieve the next level of growth," stated Mr. Shreiner.
Mr. Shreiner is a member of the Board of Directors of Global Partnership for Afghanistan. Mr. Shreiner received a B.B.A. in Accounting from Kent State University and an M.B.A in Banking & Finance from the Weatherhead School of Management at Case Western Reserve University.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Kristen Sheppard, firstname.lastname@example.org
|SOURCE NxStage Medical, Inc.|
Copyright©2012 PR Newswire.
All rights reserved